DnB Asset Management AS Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

DnB Asset Management AS raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 35,804 shares of the biopharmaceutical company’s stock after purchasing an additional 2,685 shares during the period. DnB Asset Management AS’s holdings in Regeneron Pharmaceuticals were worth $25,504,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of REGN. State Street Corp boosted its stake in Regeneron Pharmaceuticals by 1.3% during the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after acquiring an additional 61,277 shares in the last quarter. Loomis Sayles & Co. L P lifted its holdings in shares of Regeneron Pharmaceuticals by 33.4% during the fourth quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company’s stock valued at $1,122,168,000 after purchasing an additional 393,997 shares during the last quarter. Amundi boosted its position in shares of Regeneron Pharmaceuticals by 45.8% in the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock worth $1,138,074,000 after purchasing an additional 487,489 shares in the last quarter. Norges Bank purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $802,036,000. Finally, Charles Schwab Investment Management Inc. increased its position in Regeneron Pharmaceuticals by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 695,799 shares of the biopharmaceutical company’s stock valued at $495,639,000 after buying an additional 22,538 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. BMO Capital Markets cut their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 4th. Robert W. Baird reduced their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research note on Wednesday, February 5th. Sanford C. Bernstein dropped their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Finally, Bank of America reaffirmed an “underperform” rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Stock Up 0.2 %

REGN opened at $637.36 on Friday. The stock has a market cap of $69.68 billion, a price-to-earnings ratio of 16.65, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The firm’s fifty day moving average is $683.88 and its 200 day moving average is $800.34. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $629.02 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $11.86 earnings per share. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.55%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.